Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 160
- Registration Number
- NCT01498562
- Locations
- 🇰🇷
Severance hospital, Yonsei Cancer Center, Seoul, Korea, Republic of
Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Seoul Veterans Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01485809
- Locations
- 🇰🇷
Seoul Veterans Hospital, Seoul, Korea, Republic of
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 195
- Registration Number
- NCT01469000
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 319
- Registration Number
- NCT01466660
- Locations
- 🇫🇷
CTR Leon Berard, Lyon, France
🇬🇧Western General Hospital, Edinburgh, United Kingdom
🇨🇳Cancer Hospital of Chinese Academy of Medical Science, Beijing, China
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 222
- Registration Number
- NCT01405079
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, China
Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Target Recruit Count
- 32
- Registration Number
- NCT01405846
- Locations
- 🇬🇧
Papworth Hospital NHS Trust, Papworth Everard, Cambs, United Kingdom
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 219
- Registration Number
- NCT01404260
- Locations
- 🇨🇳
Shanghai Lung Tumor Clinical Center,Shanghai Chest Hospital, Shanghai, Shanghai, China
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- University College, London
- Target Recruit Count
- 38
- Registration Number
- NCT01310855
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇬🇧Southampton General Hospital, Southampton, United Kingdom
🇬🇧Royal Marsden Hospital, Sutton, United Kingdom
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2011-02-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT01291823
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1060
- Registration Number
- NCT01203917
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.